The Chicago Entrepreneur

Alumis eyes $300 million in proceeds in IPO

California-based biopharmaceutical company plans to trade on the Nasdaq under the symbol ALMS.

Previous post The S&P 500 is headed for 15,000 by the end of the decade, says Tom Lee, who foresaw the 2023 rally
Next post Security breach reports send Farcana (FAR) crushing 60%